» Articles » PMID: 16987049

Durability of Adherence to Antiretroviral Therapy on Initial and Subsequent Regimens

Overview
Date 2006 Sep 22
PMID 16987049
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

There is uncertainty regarding the durability of adherence to antiretroviral therapy. This study is a retrospective review of previously antiretroviral naïve patients initiating therapy between 1997 and 2002. Antiretroviral adherence was calculated using prescription refill data and was analyzed over time on an initial regimen and on sequential antiretroviral regimens. Three hundred forty-four patients were included. The median lengths of the first, second, and third regimens were stable at 1.7 years, 1.2 years, and 1.5 years, respectively (p = 0.10). In multivariate analysis the factor most significantly associated with earlier initial regimen termination was poor adherence. On an initial regimen, adherence decreased over time and declined most rapidly in patients with the shortest regimens (4 to <16 months, -43% per year), followed by patients with intermediate regimen duration (16 to <28 months, -19% per year), and then patients with longer regimens (>/=28 months, -5% per year). In patients progressing to a third regimen, there was a trend toward decreasing adherence over successive regimens. In conclusion, sequential antiretroviral regimens are of similar lengths, with adherence being highly associated with first regimen duration. Adherence decreases during an initial regimen and on sequential antiretroviral regimens. Effective and durable interventions to prevent declining adherence are needed.

Citing Articles

Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus.

Vernon F, Morrow M, MaWhinney S, Coyle R, Coleman S, Ellison L Open Forum Infect Dis. 2020; 7(10):ofaa391.

PMID: 33072812 PMC: 7539687. DOI: 10.1093/ofid/ofaa391.


Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico.

Martinez-Salazar M, Oaxaca-Navarro J, Leija-Salas A, Garcia-Jimenez S, Sanchez-Aleman M, Deciga-Campos M Eur J Hosp Pharm. 2019; 25(6):322-326.

PMID: 31157050 PMC: 6319403. DOI: 10.1136/ejhpharm-2016-001106.


Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.

Castillo-Mancilla J, Morrow M, Coyle R, Coleman S, Gardner E, Zheng J Clin Infect Dis. 2018; 68(8):1335-1342.

PMID: 30137238 PMC: 6451996. DOI: 10.1093/cid/ciy708.


Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression.

Castillo-Mancilla J, Morrow M, Boum Y, Byakwaga H, Haberer J, Martin J J Acquir Immune Defic Syndr. 2018; 77(5):507-513.

PMID: 29346185 PMC: 5844840. DOI: 10.1097/QAI.0000000000001629.


Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.

Castillo-Mancilla J, Brown T, Erlandson K, Palella Jr F, Gardner E, Macatangay B Clin Infect Dis. 2016; 63(12):1661-1667.

PMID: 27660234 PMC: 5146724. DOI: 10.1093/cid/ciw650.


References
1.
Mocroft A, Youle M, Moore A, Sabin C, Madge S, Lepri A . Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001; 15(2):185-94. DOI: 10.1097/00002030-200101260-00007. View

2.
Liu H, Golin C, Miller L, Hays R, Beck C, Sanandaji S . A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001; 134(10):968-77. DOI: 10.7326/0003-4819-134-10-200105150-00011. View

3.
Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E . The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001; 28(3):232-9. DOI: 10.1097/00042560-200111010-00005. View

4.
Rigsby M, Rosen M, Beauvais J, Cramer J, Rainey P, OMalley S . Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med. 2000; 15(12):841-7. PMC: 1495713. DOI: 10.1046/j.1525-1497.2000.00127.x. View

5.
dArminio Monforte A, Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips A . Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS. 2000; 14(5):499-507. DOI: 10.1097/00002030-200003310-00005. View